A single nanobody neutralizes multiple epochally evolving human noroviruses by modulating capsid plasticity

Human noroviruses cause widespread acute gastroenteritis with limited treatment options. GII.4 strains dominate global outbreaks and evolve rapidly, altering antigenic and cell attachment profiles. This evolution complicates vaccine and drug development. Prior research has shown that these viruses bind to histo-blood group antigens to infect cells. However, no broadly effective antiviral agents exist. Understanding how antibodies can target conserved viral features remains a key challenge. Dynamic structural changes in viral capsids are known to influence infection mechanisms. Yet, the role of antibody-induced conformational shifts in neutralization is not fully understood. This gap motivated investigations into how antibodies might access hidden epitopes during viral conformational transitions. The absence of broad-spectrum antivirals for norovirus highlights the need for new therapeutic strategies.

This research aimed to identify a broad-spectrum antiviral agent against evolving GII.4 norovirus strains. The goal was to test whether a llama-derived nanobody could neutralize multiple variants. Researchers focused on understanding how the nanobody interacts with the virus's capsid structure. They sought to determine if the nanobody could access conserved epitopes across different strains. The study also aimed to explore how the nanobody affects capsid conformational dynamics. Structural analysis was used to map epitope accessibility during capsid transitions. The researchers wanted to assess whether the nanobody could trigger capsid disassembly. This approach could lead to new insights into norovirus neutralization mechanisms.

The study used a llama-derived nanobody named M4 to test its neutralizing activity against multiple GII.4 norovirus variants. Researchers tested M4 in human intestinal enteroids to assess antiviral potency. They determined the crystal structure of M4 bound to the VP1 protruding domain of the GII.4 capsid. Dynamic light scattering was used to observe capsid conformational changes. Electron microscopy provided structural insights into virus-like particles. The team analyzed how M4 binding affects capsid plasticity and stability. They evaluated epitope conservation across different GII.4 strains. The study combined structural biology with functional assays to understand neutralization mechanisms.

M4 neutralized multiple GII.4 norovirus variants with high potency in human intestinal cells. Structural analysis revealed a conserved epitope on the VP1 protruding domain. This epitope is accessible only when the capsid adopts a 'raised' conformation. M4 binding was associated with capsid conformational shifts and disassembly. Dynamic light scattering showed altered capsid dynamics upon M4 binding. Electron microscopy confirmed structural changes in virus-like particles. The epitope is distinct from the histo-blood group antigen binding site. These findings suggest that M4 neutralizes GII.4 by triggering capsid instability.

The study demonstrates that M4 can neutralize multiple GII.4 norovirus strains by targeting a conserved epitope. The nanobody accesses this site only when the capsid undergoes a conformational change. This mechanism suggests that M4 induces capsid disassembly to block infection. The epitope is distinct from the histo-blood group antigen binding region. These findings support the idea that capsid plasticity is crucial for norovirus neutralization. The study highlights the potential of using nanobodies to target conserved epitopes. The results suggest that M4 could serve as a broad-spectrum antiviral candidate. Further research may explore how to optimize this approach for therapeutic applications.